LAWRENCE, Mass., Oct. 21, 2016 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today announced that it is participating in the Partners Healthcare Connected Health Symposium and Expo today, Friday, October 21, 2016 in Boston, MA. More specifically, NxStage is showcasing recent data associated with its Nx2me Connected Health® platform that shows a significantly reduced risk of home hemodialysis (HHD) attrition with HHD patients using this solution. Lower risk is particularly pronounced during the patients' first months performing HHD therapy with the NxStage® System One™.
"As a leader in home dialysis, NxStage has been at the forefront of connected health with innovative technology that enables connectivity and supports data sharing between home patients and their care teams," said Joseph E. Turk, president of NxStage. "We're excited to be showcasing our capabilities in this area with Nx2me data that continues to reaffirm how these innovations help ensure better success at home for patients."
A key component of the Nx2me platform is the Nx2me iPad® app, which is designed to increase patients' ease of use of home therapy by monitoring and capturing treatment data and wirelessly sending it to their center after each treatment, thereby reducing the need for paper flow sheets. Dialysis center staff can access the treatment data using the Nx2me Clinician Portal to review and follow treatment adherence and progress. Importantly, Nx2me patient treatment data can be easily integrated into EMR systems.
For more information about Nx2me and HHD with the NxStage System One, please visit www.NxStage.com.
For more information about the Partners Healthcare Connected Health Symposium and Expo 2016, please visit https://symposium.connectedhealth.org/.
* Lower Risk of Home Hemodialysis Attrition in Patients Using Nx2me Connected Health Technology. J Molina, P Kravitz, E Weinhandl.
Despite the health benefits that home hemodialysis may provide to those with chronic kidney disease, this form of therapy is not for everyone. The reported benefits of home hemodialysis may not be experienced by all patients. The risks associated with hemodialysis treatments in any environment include, but are not limited to, high blood pressure, fluid overload, low blood pressure, heart-related issues, and vascular access complications. The medical devices used in hemodialysis therapies may add additional risks including air entering the bloodstream and blood loss due to clotting or accidental disconnection of the blood tubing set. Certain risks are unique to the home. Treatments at home are done without the presence of medical personnel and on-site technical support. Patients and their partners must be trained on what to do and how to get medical or technical help if needed.
About the NxStage System One
The NxStage System One is the first and only truly portable hemodialysis system cleared specifically by the FDA for home hemodialysis and home nocturnal hemodialysis. Its simplicity and revolutionary size (just over a foot tall) are intended to allow convenient use in patients' homes and give patients the freedom to travel with their therapy. When combined with the NxStage PureFlow SL Dialysis Preparation System, patients are able to further simplify, using ordinary tap water to create dialysis fluid on demand. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency. In addition, NxStage's Nx2me Connected Health platform collects important NxStage System One and patient information for flexible viewing, monitoring and reporting that may improve patient management and patient retention, as well as simplify alternative site care. http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a leading medical technology company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. NxStage also has established a small number of dialysis clinics committed to the development of innovative care delivery models for patients with ESRD. For more information on NxStage and its products and services, please visit the Company's websites at www.nxstage.com andwww.nxstagekidneycare.com.
This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended June 30, 2016. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen K. Sheppard, Esq.
Tel: (978) 332-5923
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nxstage-highlights-innovative-nx2me-platform-data-at-partners-healthcare-connected-health-symposium--expo-2016-300349010.html
SOURCE NxStage Medical, Inc.